Cell Signalling and Targeted Therapy
Photo: Mostphotos

The cell signalling and targeted therapy group perform basic research into the mechanism of cancer cell signalling with the aim to identify novel strategies for cancer therapy.

We are particularly interested in understanding how specific protein kinases and protein phosphatases contributes to these processes.

Our research projects includes studies of

  • Role of DUSP2 in cancer cell signaling in hematological malignancies

  • Stress activated signaling pathways in cancer development

  • Targeting tissue acidosis in solid tumours


We are also involved in several collaborative projects within the Faculty of Health Sciences (Link microRNA), the University of Tromsø and the Norwegian Cancer Genomics Consortium (link).

The research in our group is made possible with grants from the Norwegian Cancer society, Norwegian research Council, Helse Nord, and the Blix foundation.

Projects



Targeting Tissue Acidosis in Solid Tumours
Role of DUSP2 in cancer cell signaling in hematological malignancies
Stress activated signaling pathways in cancer development

Latest news


Members


Latest publications

2026

Henrike Bruckmueller, Anangi Balasiddaiah, Sofia Malek, Victoria Tenhaken, Julien Bruckmueller, Jakob Mejlvang, Helene Spangenberg, Farah Syed, Bjarne Johansen, Hanne Kildalsen, Ingolf Cascorbi, Ole-Morten Seternes
The dual specificity phosphatase 2 act as distal regulatory node in T cell signaling, iScience 29, 116690, August 21, 2026

2025

Maria Dravecka, Ingvild Mikkola, Terje Johansen, Ole Morten Seternes, Jakob Mejlvang
Low extracellular pH protects cancer cells from ammonia toxicity, Cell Death Discovery, 137(2025)

Victoria Tenhaken, Ole-Morten Seternes, Ingolf Cascorbi, Henrike Bruckmueller
The MAP kinase negative regulator DUSP2 (dual specificity phosphatase 2) is controlled by oncogenic microRNA cluster miR-17-92, miR-106a-363 and miR-106b-25, BMC Cancer (25, 1020), 2025

Sofia Morazzo, Soraia Fernandes, Marina Fortea, Helena Ska´lova´, Daniel Pereira-Sousa, Marco Cassani, Kamila Vrzalova´, Filip Kafka, Jan Vrbsky´, Mathilde Soulez, Sylvain Meloche, Ole Morten Seternes, Veronika Bosa´kova´, Jaeyoung Shin, Jan Fricˇ, Kristina Haase, Giancarlo Forte
ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity. Front. Oncol., 27 August 2025

Maria Dravecka, Claire Wells, Ole Morten Seternes, Jakob Mejlvang
The effect of acute and prolonged acidosis on a panel of carcinoma cell lines Advances in Cancer Biology - Metastasis, Volume 15, Dec 2025

2023

Boudghene-Stambouli, Fadia; Soulez, Mathilde; Ronkina, Natalia; Dörrie, Anneke; Kotlyarov, Alexey; Seternes, Ole Morten; Gaestel, Matthias; Meloche, Sylvain.
On the Therapeutic Potential of ERK4 in Triple-Negative Breast Cancer. Cancers 2023 ;Volum 15.(1)  UiT

Tislevoll, Benedicte Sjo; Hellesøy, Monica; Fagerholt, Oda Helen Eck; Gullaksen, Stein-Erik; Srivastava, Aashish; Birkeland, Even; Kleftogiannis, Dimitrios; Ayuda Duran, Pilar; Piechaczyk, Laure Isabelle; Tadele, Dagim Shiferaw; Skavland, Jørn; Panagiotis, Baliakas; Hovland, Randi; Andresen, Vibeke; Seternes, Ole Morten; Tvedt, Tor Henrik Anderson; Aghaeepour, Nima; Gavasso, Sonia; Porkka, Kimmo; Jonassen, Inge; Fløisand, Yngvar; Enserink, Jorrit; Blaser, Nello; Gjertsen, Bjørn Tore.
Early response evaluation by single cell signaling profiling in acute myeloid leukemia. Nature Communications 2023 ;Volum 14.(1) s. - UiB HAUKELAND UiO OUS UiT
 

2022

Javary, Joaquim; Goupil, Eugénie; Soulez, Mathilde; Kanshin, Evgeny; Bouchard, Antoine; Seternes, Ole Morten; Thibault, Pierre; Labbé, Jean-Claude; Meloche, Sylvain.
Phosphoproteomic analysis identifies supervillin as an ERK3 substrate regulating cytokinesis and cell ploidy. Journal of Cellular Physiology 2022 s. -
UiT

Kaehler, Meike; Litterst, Merit; Kolarova, Julia; Bohm, Ruwen; Bruckmüller, Henrike; Ammerpohl, Ole; Cascorbi, Ingolf; Nagel, Inga.
Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells. Oncology Reports 2022 ;Volum 48.(2) s. -
UiT

 Zeyen Øyås, Lisa; Seternes, Ole Morten; Mikkola, Ingvild.
Crosstalk between p38 MAPK and GR Signaling. International Journal of Molecular Sciences 2022 ;Volum 23.(6) s. -
UiT

 

Collaborators

Local collaborators:

National collaborators:

 International collaborators: 

Cell Signalling and Targeted Therapy


Prof. Ole Morten Seternes, Dept. of Pharmacy, Faculty of Health sciences, University of Tromsø

During last 20 years our research group has educated the following master students and phd candidates.

Phd thesis

MASTER PROJECT

År Etternavn Fornavn Tittel
2005 Ånonli Aileen Påvisning av BCR-ABL mutasjoner som gir resistens mot Glivec i behandling av pasienter med KML og ALL.
2006 Johansen Linda Eilen Targeted detection of mutations associated with imatinib-resistance.
2006 Hammer Stine Gangnæs Cloning and expression of wild-type and mutated forms of Bcr-Abl in a mouse pro-B cell line.
2006 Myrland Linn-Karina Mapping of Pax6 binding site(s) in a putative CREM enhancer.
2006 Eriksen Tonje Engevik Construction of inducible cell-lines for the transcription factor Pax6.
2007 Anthonsen Elin Benberg Use of electrophoration and magnetic cell sorting for the expression of Bcr-Abl in a mouse pro-B cell line.
2009 Weibust Elisabeth Identifisering av PAX og MMP uttrykk i tre prostatakreft cellelinjer.
2009 Nguyen Lan Huong Thi Identifisering av en gruppe glykosyltransferaser som mulige målgener for transkripsjonsfaktoren Pax6.
       
       
Logg inn / Login